Genetic testing services provider NeoGenomics will use Thermo Fisher Scientific’s Ion Torrent Genexus System— a next-generation sequencing (NGS) solution that automates the specimen-to-report workflow to quickly deliver results—in a pharma-sponsored Phase 1 study of myeloid cancer.
As part of the preclinical research investigation, NeoGenomics will receive early access to Thermo Fisher’s new Oncomine Myeloid Assay GX v2 to validate the assay on the Genexus System. The assay is designed to optimize variant detection, covering key genes and fusions across the myeloid cancer spectrum.
“We have worked with Thermo Fisher Scientific in multiple genomic initiatives and are excited to leverage their Genexus System to deliver comprehensive genomic data with unprecedented speed,” says Mark Mallon, CEO of NeoGenomics. “By compressing turnaround time for results from weeks to days we can ensure researchers have the data they need to accelerate progress as they look to develop critically needed myeloid cancer treatments in the future.”
Thermo Fisher introduced the Oncomine Myeloid Assay GX v2 at the American Society of Hematologists (ASH) Annual Meeting & Exposition.
“Myeloid cancers such as acute myeloid leukemia present unique challenges due to their heterogeneity and sample complexity,” says Garret Hampton, president of clinical sequencing and oncology, Thermo Fisher Scientific. “NGS allows researchers to profile all key mutations simultaneously, saving time compared to sequential single-gene testing. By combining the speed of the Genexus System with NeoGenomics’ expertise and data services, we hope to advance discoveries that will inform future therapeutic development for patients who desperately need new treatment options.”
